In individual studies, MCT1 immunoreactivity scores were significantly increased in 24 high-grade patient samples of GBM and anaplastic astrocytoma compared with 24 low-grade patient samples of oligodendrogliomas and low-grade astrocytomas [52], and it was significantly increased in 78 GBM patient samples compared with 24 non-tumor brain samples [53]. This evidence concerns the gene SLC16A1 and neoplasm.